Seikagaku Corporation
Stock Price Chart
2026/07/10 UpdatedPrice Trend
2026/07/10 UpdatedPrice & Trading Details
2026/07/10 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/07/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2016/02/01 | ¥40.50 | ¥18.93 | -53.3% |
| 2015/02/02 | ¥13.60 | ¥23.85 | +75.4% |
Shareholder Composition
Updated 2026/07/01Major Holders
Updated 2026/07/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
510.5K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
350.4K | 0.00% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
181.1K | +68.31% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap
|
115.8K | -10.64% | |
|
Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund
|
101.8K | -18.69% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
83.1K | -43.78% |
Dividend History
Updated 2026/07/05| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥15 | -50.0% |
| 2025 | ¥30 | +7.1% |
| 2024 | ¥28 | +7.7% |
| 2023 | ¥26 | -7.1% |
| 2022 | ¥28 | - |
Financial Performance
2026/07/05 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥33,456M | ¥36,213M | ¥39,374M | ¥36,645M |
| Gross Profit | ¥18,024M | ¥16,877M | ¥19,153M | ¥15,972M |
| Operating Income | ¥2,116M | ¥434M | ¥1,336M | -¥658M |
| Pretax Income | ¥3,074M | ¥1,695M | ¥1,937M | ¥1,519M |
| Net Income | ¥2,236M | ¥2,186M | ¥1,214M | ¥1,473M |
| EPS | ¥40.49 | ¥40.08 | ¥22.25 | ¥26.99 |
| Operating Margin | 6.32% | 1.20% | 3.39% | -1.80% |
| Balance Sheet | ||||
| Total Assets | ¥75,625M | ¥81,795M | ¥83,872M | ¥86,344M |
| Total Equity | ¥67,216M | ¥72,281M | ¥73,185M | ¥75,298M |
| Total Liabilities | ¥8,409M | ¥9,514M | ¥10,687M | ¥11,046M |
| Cash | ¥23,451M | ¥15,439M | ¥15,132M | ¥8,938M |
| Interest-bearing Debt | ¥389M | ¥396M | ¥380M | ¥356M |
| Equity Ratio | 88.88% | 88.37% | 87.26% | 87.21% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥1,574M | ¥513M | ¥4,429M | -¥1,347M |
| Investing CF | ¥3,365M | -¥7,209M | -¥3,540M | -¥3,508M |
| Financing CF | -¥3,244M | -¥1,461M | -¥1,571M | -¥1,677M |
| Free CF | -¥478M | -¥4,047M | -¥179M | -¥7,371M |
| Efficiency | ||||
| ROE | 3.33% | 3.02% | 1.66% | 1.96% |
| ROA | 2.96% | 2.67% | 1.45% | 1.71% |
Latest IR Information
-
Notice on the Completion of Payment for the Transfer-Restricted Stock as Share Compensation
Payment completion for disposal of treasury stock as transfer-restricted stock-based remuneration. Number of disposal shares: 22,436 ordinary shares; total amount: JPY 16,288,536. Disposals to four directors (excluding outside directors) and two executive officers (excluding those who also serve as directors):...
Read more -
Notice Regarding the Disposal of Treasury Shares as Restricted Stock Compensation
Read more
Latest News (5 items)
Company Information
About
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. It operates in two segments, Pharmaceuticals and LAL Business. The company offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, JOYCLU Gel-One, Hylink, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and HERNICORE for the treatment of lumbar disc herniation. It also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, the company develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals and medical devices manufacturing processes and water quality control of dialysate used in artificial dialysis. Further, its products under development include SI-6603 for lumbar disc herniation; SI-614, a dry eye treatment; SI-613 for osteoarthritis; SI-722 to treat interstitial cystitis and bladder pain syndrome; SI-613-ETP to treat enthesopathy; and SI-449, a cross-linked chondroitin sulfate adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was incorporated in 1947 and is headquartered in Tokyo, Japan.